Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc.

Molecular diagnostics market size to reach USD 38.01 billion by 2034: Polaris Market Research: United States Thursday, February 19, 2026, 09:00 Hrs [IST] The molecular diagnostics ...

Gene expression experiments measure changes in RNA transcript levels to compare how genes are up- or down-regulated across ...

Increase in prevalence of genetic disorders, shift towards personalized medicine, and surge in demand for forensic DNA ...

Moby Strategic Performance Drivers and Operational Context. Management attributed the Q4 gross margin miss to execution- ...

Bio-Rad Laboratories Inc (BIO) reports a 3.9% sales increase in Q4 2025, driven by diagnostics growth, despite supply chain and market headwinds.

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this time, I ...

Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended ...

The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

Aim. Human Papillomaviruses (HPVs) have been implicated in the pathogenesis of different skin and mucosal epithelial lesions. These viruses can cause a variety of benign lesions of the genital mucosa ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announces it has received validation from AOAC International for its ...